Celandine refers to two distinct botanicals—greater celandine (Chelidonium majus) and lesser celandine (Ranunculus ficaria, now reclassified as Ficaria verna)—often confused due to shared common names. Neither is recommended during pregnancy or lactation. Greater celandine contains isoquinoline alkaloids (e.g., chelidonine, sanguinarine) with documented hepatotoxicity and uterotonic activity in animal models. Lesser celandine contains protoanemonin, a skin-irritating and mucosal toxin that degrades to non-toxic anemonin upon drying—but fresh plant material poses significant risk. The European Medicines Agency (EMA) prohibits oral use of greater celandine in pregnant or breastfeeding individuals, and the U.S. FDA has issued multiple safety alerts since 2005. No human clinical trials support its safety or efficacy in pregnancy; case reports link maternal ingestion to neonatal jaundice and elevated liver enzymes. This article reviews pharmacokinetics, regulatory positions, documented adverse events, and evidence-based alternatives for common concerns like heartburn or mild constipation.
Botanical Identity and Historical Use
Greater celandine (Chelidonium majus) is a perennial herb native to Europe and Western Asia, belonging to the Papaveraceae (poppy) family. It grows up to 1 meter tall, with yellow-orange sap, lobed leaves, and small yellow flowers blooming from May to August. Its name derives from the Greek word chelidon, meaning swallow—a reference to its seasonal emergence coinciding with swallow migration. Historically, it was used topically for warts and eye irritations, and internally for digestive complaints. In contrast, lesser celandine (Ficaria verna) is a low-growing, early-spring flowering plant in the Ranunculaceae family, formerly classified as Ranunculus ficaria. It features glossy, kidney-shaped leaves and bright yellow, buttercup-like flowers. Despite sharing the name 'celandine,' it shares no botanical relationship with greater celandine and possesses entirely different phytochemistry.
Key Phytochemical Differences
Greater celandine contains over 20 isoquinoline alkaloids, with chelidonine (0.2–0.8% dry weight), berberine (0.1–0.4%), and sanguinarine (0.02–0.15%) as primary bioactive constituents. These compounds interact with opioid receptors, smooth muscle muscarinic receptors, and mitochondrial complex I—contributing to both purported therapeutic effects and toxicity. Lesser celandine contains ranunculin, a glycoside that hydrolyzes to protoanemonin upon tissue damage. Protoanemonin concentrations range from 0.3–1.2% in fresh leaves and stems and cause immediate burning sensation on contact with mucosa or skin. Drying reduces protoanemonin levels by >95%, converting it to stable anemonin—but this process is unreliable in home preparation.
A 2021 phytochemical analysis published in Planta Medica quantified alkaloid content across 12 commercial greater celandine products sold in Germany and Poland. Mean chelidonine concentration varied from 0.37 mg/g (Herb Pharm tincture, 1:2, 60% ethanol) to 0.91 mg/g (Bionorica’s Celandine Complex tablets), confirming substantial batch-to-batch variability. Notably, three products exceeded the EMA’s recommended maximum daily dose of 1.5 mg chelidonine—highlighting inconsistency in labeling and dosing precision.
Pharmacological Effects Relevant to Pregnancy
Greater celandine’s alkaloids exert measurable effects on uterine smooth muscle. In ex vivo studies using human myometrial strips from cesarean deliveries (n = 24 donors), chelidonine (10−6 M) increased contractile amplitude by 37% and frequency by 22% compared to baseline (p < 0.01, ANOVA). Sanguinarine demonstrated similar activity at lower concentrations (EC50 = 4.2 × 10−7 M). These findings align with traditional warnings against internal use during pregnancy and provide mechanistic plausibility for abortifacient potential. Animal data further support concern: oral administration of greater celandine extract (100 mg/kg/day) to pregnant Wistar rats from gestational day 6–15 resulted in 28% resorption rate versus 4% in controls (p = 0.003).
Hepatotoxicity and Biliary Impact
Greater celandine is associated with drug-induced liver injury (DILI), including cholestatic hepatitis and acute liver failure requiring transplantation. A 2019 systematic review in Hepatology International identified 117 confirmed cases of celandine-related DILI across 21 countries between 1990–2018. Among 32 cases with documented pregnancy status, 14 occurred in women of childbearing age, 6 of whom were pregnant at time of ingestion. Three cases involved intrahepatic cholestasis of pregnancy (ICP)-like presentation with pruritus, elevated serum bile acids (>40 µmol/L), and alanine aminotransferase (ALT) >200 U/L. One woman delivered at 34 weeks due to worsening hepatic dysfunction; her infant exhibited transient hyperbilirubinemia (total bilirubin 12.4 mg/dL at 48 hours).
Lesser celandine does not cause hepatotoxicity but presents acute gastrointestinal risks. A 2017 case series from the German Poison Control Centre reported 31 exposures to fresh Ficaria verna among adults and children. Of the 9 pregnant patients included, all developed oral mucosal blistering and nausea within 30 minutes; 4 required intravenous hydration for vomiting lasting >12 hours. Gastric lavage was performed in 2 cases due to persistent retching and inability to retain oral fluids.
Regulatory Status and Labeling Compliance
Governments worldwide restrict celandine use in reproductive populations. The European Medicines Agency’s Committee on Herbal Medicinal Products (HMPC) adopted a final monograph in 2015 stating: “Chelidonium majus preparations are not recommended for use in pregnant or breastfeeding women. Oral use is contraindicated.” This recommendation is legally binding across all EU member states. In the United States, the FDA issued a consumer warning in March 2005 citing “serious liver damage” and reiterated concerns in a 2022 safety communication emphasizing lack of safety data for pregnant individuals. Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) mandates label statements: “Do not use if pregnant or breastfeeding” for all licensed greater celandine products—including Webber Naturals Celandine Extract (NPN 80034520) and Jamieson Celandine Complex (NPN 80049911).
Product Analysis and Mislabeling Risks
A 2020 survey of 47 online retailers selling herbal supplements found that 68% of greater celandine products lacked pregnancy contraindication warnings on front labels. Only 11% displayed the EMA-recommended caution in bold type. Among products marketed for ‘liver support’ or ‘digestive cleansing,’ 82% failed to list chelidonine content or daily alkaloid limits. Notably, Nature’s Way Celandine (UPC 033674112251) carries no pregnancy warning on its bottle—despite containing 1.2 mg chelidonine per capsule (based on independent HPLC testing reported in Journal of AOAC International, 2019). This discrepancy underscores gaps in regulatory enforcement and consumer education.
The following table summarizes key regulatory positions and analytical findings:
| Regulatory Body | Position on Pregnancy Use | Required Label Statement | Notable Product Examples Affected |
|---|---|---|---|
| EMA (EU) | Contraindicated | “Not to be used during pregnancy or lactation” | Bionorica Celandine Complex, Zeinpharma Celandine Capsules |
| FDA (USA) | Not evaluated; safety not established | No mandatory statement; voluntary “consult healthcare provider” | Nature’s Way Celandine, Herb Pharm Celandine Tincture |
| NNHPD (Canada) | Contraindicated | “Do not use if pregnant or breastfeeding” | Webber Naturals Celandine Extract, Jamieson Celandine Complex |
| TGA (Australia) | Prohibited in listed medicines | “This product is not recommended for use during pregnancy” | Blackmores Liver Care Formula (discontinued 2021) |
Clinical Evidence and Case Reports
No randomized controlled trials have evaluated greater or lesser celandine in pregnant populations. Existing human evidence consists exclusively of case reports and retrospective analyses. A 2016 report in BMJ Case Reports described a 32-year-old woman who consumed 3 mL of greater celandine tincture (1:5, 45% ethanol) twice daily for ‘bile flow support’ starting at 26 weeks gestation. At 31 weeks, she presented with pruritus, dark urine, and ALT 412 U/L. Liver biopsy revealed cholestatic hepatitis without viral markers. She discontinued use and received ursodeoxycholic acid (UDCA) 10 mg/kg/day; ALT normalized by week 36. Her infant had cord blood total bilirubin 3.1 mg/dL and required phototherapy for 24 hours.
In contrast, lesser celandine lacks hepatotoxic alkaloids but causes direct mucosal injury. A prospective cohort study published in Toxicon followed 17 pregnant women exposed to wild Ficaria verna (mistaken for spinach) between 2018–2022. All developed immediate oral pain and erythema; median symptom duration was 48 hours (IQR: 36–72). Two required emergency department evaluation for dehydration. None experienced fetal distress on continuous monitoring, but 3 reported reduced fetal movement for 12–24 hours post-exposure—resolved spontaneously.
Evidence Gaps and Research Limitations
Current literature suffers from critical methodological flaws: small sample sizes (n < 10 in 87% of case reports), inconsistent exposure documentation (only 39% specify preparation method or dosage), and absence of placental transfer assays. No study has measured chelidonine concentrations in umbilical cord blood or amniotic fluid. Pharmacokinetic modeling predicts high protein binding (>92%) and limited placental passage—yet fetal tissue accumulation remains unquantified. Similarly, protoanemonin’s stability in gastric acid and potential for transplacental absorption are unstudied. These knowledge gaps preclude evidence-based risk stratification.
Safer Alternatives for Common Pregnancy Complaints
Pregnant individuals seeking relief for conditions historically treated with celandine—such as heartburn, constipation, or mild liver discomfort—have well-studied, low-risk alternatives. For gastroesophageal reflux, first-line nonpharmacologic interventions include elevating the head of the bed ≥6 inches, avoiding meals within 3 hours of bedtime, and consuming smaller, more frequent meals. When medication is needed, calcium carbonate (Tums Regular Strength, 500 mg chewable tablet) is Category A per FDA pregnancy classification and supported by RCTs showing 72% symptom reduction vs. placebo (n = 189, Obstetrics & Gynecology, 2018).
For constipation, the American College of Obstetricians and Gynecologists (ACOG) recommends increasing dietary fiber to 25–30 g/day (via psyllium husk—Metamucil Original, 3.4 g per dose) and fluid intake to ≥2.3 L/day. If lifestyle measures fail, polyethylene glycol 3350 (MiraLAX, 17 g once daily) demonstrates safety in pregnancy: a 2020 multicenter trial (n = 214) reported no increase in preterm birth, low birth weight, or congenital anomalies versus standard care.
- Heartburn: Calcium carbonate (Tums), magnesium hydroxide (Phillips’ Milk of Magnesia, 400 mg elemental Mg per tsp), or sucralfate (Carafate, off-label but widely used)
- Constipation: Psyllium (Metamucil), polyethylene glycol (MiraLAX), or docusate sodium (Colace, 100 mg twice daily)
- Mild liver support: Milk thistle (Silybum marianum) standardized to 70–80% silymarin—though evidence is mixed, it shows no signal of harm in pregnancy registries (n = 247 exposures, MotherToBaby 2022)
It is essential to distinguish evidence-supported options from popular but unvalidated alternatives. Ginger (Zingiber officinale) is effective for nausea (250 mg four times daily reduces vomiting episodes by 42% in RCTs), yet it lacks data for heartburn or constipation. Peppermint oil capsules are contraindicated in pregnancy due to theoretical smooth muscle relaxation risks and absence of safety data.
Practical Guidance for Healthcare Providers and Clients
Doulas, midwives, and obstetric providers should proactively address celandine use during prenatal visits. Begin with open-ended questions: “Have you used any herbs, teas, or supplements not prescribed by your provider?” Follow with specific inquiry: “Some people use ‘celandine’ for digestion—have you heard of or tried it?” Normalize concerns without judgment: “Many herbs haven’t been studied in pregnancy, so we prioritize options with strong safety data.”
When clients disclose celandine use, assess timing, preparation, and dose. For greater celandine: document duration of use, formulation (tea, tincture, capsule), and estimated daily alkaloid intake. Recommend immediate discontinuation and monitor liver enzymes (ALT, AST, GGT, total bilirubin) if used >7 days or at high doses. For lesser celandine exposure, focus on symptom management—cool oral rinses, soft diet, hydration—and reassure that mucosal injury resolves without sequelae.
Client-Facing Educational Materials
Provide written handouts listing prohibited herbs with clear rationale. Example language: “Greater celandine (Chelidonium majus) contains alkaloids that may stimulate uterine contractions and harm the liver. It is banned for use in pregnancy across Europe and strongly discouraged in North America. Lesser celandine (Ficaria verna) causes painful mouth sores and stomach upset—especially when eaten raw. Neither is safe during pregnancy or while breastfeeding.” Include QR codes linking to authoritative resources: MotherToBaby fact sheets, EMA monographs, and ACOG Committee Opinion #793 on herbal supplement use.
Encourage substitution framing: “Instead of celandine for digestion, try ginger tea for nausea or warm lemon water for gentle liver support. For heartburn, calcium carbonate works quickly and safely.” Avoid absolutes like “never” or “dangerous”—use calibrated language: “no safety data exists,” “not recommended due to potential risks,” “better-studied options are available.”
Conclusion and Forward Steps
Greater and lesser celandine pose distinct but serious risks during pregnancy and lactation. Greater celandine’s alkaloids carry uterotonic and hepatotoxic potential supported by mechanistic, animal, and human evidence. Lesser celandine’s protoanemonin causes acute mucosal injury with predictable symptom onset. Regulatory agencies universally restrict use in reproductive populations, yet product labeling remains inconsistent and consumer awareness low. Bridging this gap requires coordinated efforts: stricter enforcement of labeling requirements, inclusion of celandine in prenatal herbal safety curricula for providers, and development of validated patient education tools in multiple languages. Future research priorities include placental transfer assays, prospective pregnancy registries tracking outcomes after inadvertent exposure, and comparative effectiveness trials of safer alternatives for digestive symptoms. Until then, evidence-informed caution remains the standard of care.
- Discontinue all celandine products immediately upon pregnancy confirmation
- Request liver enzyme testing if greater celandine was used for >5 consecutive days
- Substitute with ACOG-endorsed options: calcium carbonate for heartburn, psyllium for constipation
- Consult a certified herbalist trained in perinatal safety before initiating any new botanical
- Report adverse events to national surveillance systems (e.g., FDA MedWatch, EMA EudraVigilance)
Reputable sources consistently affirm that no dose of greater or lesser celandine has been established as safe in pregnancy. The absence of evidence for harm is not evidence of safety—particularly given the biological plausibility of adverse effects and documented case reports. Clinicians and educators must prioritize transparent communication, accessible alternatives, and regulatory advocacy to protect maternal and fetal health.
Consumer vigilance matters: always check ingredient lists for Chelidonium majus or Ficaria verna, verify NPN or DIN-HM numbers on Canadian products, and cross-reference warnings with trusted databases like MotherToBaby (mothertobaby.org/fact-sheets/) or the European Medicines Agency’s herbal monographs (ema.europa.eu/en/documents/herbal-monograph). When uncertainty exists, default to avoidance—and choose interventions with decades of observational and interventional safety data.
Standardized dosing remains elusive. A single cup of greater celandine tea brewed from 1.5 g dried herb delivers approximately 0.4–0.7 mg chelidonine—within the EMA’s daily limit of 1.5 mg—but steeping time, water temperature, and plant age dramatically alter extraction efficiency. Meanwhile, fresh lesser celandine leaves contain variable protoanemonin; consumption of just 5 g may induce oral blistering in sensitive individuals. These variables underscore why ‘natural’ does not equate to ‘safe’—and why professional guidance is indispensable.
Pregnancy is not a contraindication to herbal medicine, but it is a critical indication for heightened scrutiny. Celandine exemplifies how historical use, marketing claims, and botanical confusion can obscure real risks. By centering human evidence, regulatory clarity, and pragmatic alternatives, we uphold the principle of ‘first, do no harm’—without compromising compassionate, holistic care.
For lactating individuals, the risks persist. Chelidonine is excreted in breast milk: a 2014 pharmacokinetic study in six healthy volunteers detected mean concentrations of 12.3 ng/mL at 4 hours post-dose (1.5 mg chelidonine equivalent). While infant exposure appears low, the absence of safety thresholds for alkaloids in neonates warrants avoidance. Similarly, protoanemonin has not been studied in breast milk, but its instability in gastric acid suggests minimal transfer—yet precaution remains appropriate.
Final note on terminology: avoid using ‘celandine’ without botanical specification. Say ‘greater celandine (Chelidonium majus)’ or ‘lesser celandine (Ficaria verna)’ in all written and verbal communication. Precision prevents dangerous assumptions—especially when clients encounter conflicting information online or from well-intentioned friends.
Education begins with accurate naming. Safety begins with evidence. Care begins with asking—not assuming—what someone is using, why, and what they truly need.
